BR112021006406A2 - forma de dosagem de gonadotrofina coriônica humana (hcg) de liberação prolongada - Google Patents

forma de dosagem de gonadotrofina coriônica humana (hcg) de liberação prolongada

Info

Publication number
BR112021006406A2
BR112021006406A2 BR112021006406A BR112021006406A BR112021006406A2 BR 112021006406 A2 BR112021006406 A2 BR 112021006406A2 BR 112021006406 A BR112021006406 A BR 112021006406A BR 112021006406 A BR112021006406 A BR 112021006406A BR 112021006406 A2 BR112021006406 A2 BR 112021006406A2
Authority
BR
Brazil
Prior art keywords
hcg
chorionic gonadotropin
human chorionic
extended release
dosage form
Prior art date
Application number
BR112021006406A
Other languages
English (en)
Inventor
Morgentaler Abraham
Catarina Ribeiro Araujo Joana
Zuidema Johan
Kacker Ravi
Steendam Rob
Original Assignee
Innocore Tech Holding B V
Mhb Labs Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Innocore Tech Holding B V, Mhb Labs Inc filed Critical Innocore Tech Holding B V
Publication of BR112021006406A2 publication Critical patent/BR112021006406A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/24—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g. HCG; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Reproductive Health (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

forma de dosagem de gonadotrofina coriônica humana (hcg) de liberação prolongada. a presente divulgação se refere a formas de dosagem de de gonadotrofina coriônica humana (hcg) de liberação prolongada ou seus derivados ou isoformas. as formas de dosagem de hcg de liberação prolongada compreendem microesferas de polímero biodegradável e proporcionam a liberação prolongada de hcg ao longo de um período de tempo desejado.
BR112021006406A 2018-10-02 2019-10-02 forma de dosagem de gonadotrofina coriônica humana (hcg) de liberação prolongada BR112021006406A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862740145P 2018-10-02 2018-10-02
PCT/NL2019/050660 WO2020071912A1 (en) 2018-10-02 2019-10-02 Extended release formulations of human chorionic gonadotropin (hcg)

Publications (1)

Publication Number Publication Date
BR112021006406A2 true BR112021006406A2 (pt) 2021-07-06

Family

ID=69063845

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112021006406A BR112021006406A2 (pt) 2018-10-02 2019-10-02 forma de dosagem de gonadotrofina coriônica humana (hcg) de liberação prolongada

Country Status (8)

Country Link
US (1) US20220062177A1 (pt)
EP (1) EP3860573A1 (pt)
JP (1) JP2022504427A (pt)
CN (1) CN113226289A (pt)
AU (1) AU2019354528A1 (pt)
BR (1) BR112021006406A2 (pt)
CA (1) CA3115186A1 (pt)
WO (1) WO2020071912A1 (pt)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019079167A1 (en) 2017-10-16 2019-04-25 Institute For Cancer Research D/B/A The Research Institute Of Fox Chase Cancer Center PEPTIDES VARIANTS OF HUMAN CHORIONIC GONADOTROPIN AND TREATMENT OF BREAST CANCER
EP4255467A1 (en) * 2020-12-07 2023-10-11 Institute For Cancer Research d/b/a The Research Institute of Fox Chase Cancer Center Treatment of females having brca1/2 mutations with human chorionic gonadotropin to reduce the risk of developing breast cancer

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5665428A (en) * 1995-10-25 1997-09-09 Macromed, Inc. Preparation of peptide containing biodegradable microspheres by melt process
CA2585024A1 (en) * 2003-10-24 2005-05-06 Azopax Therapeutics Llc Macromer-melt formulations
WO2010017215A2 (en) * 2008-08-04 2010-02-11 The Regents Of The University Of California Biodegradable microspheres and methods of use thereof
PL2696856T3 (pl) * 2011-02-16 2017-03-31 Sanzyme Limited Formulacja o kontrolowanym uwalnianiu zawierająca hCG
KR101889586B1 (ko) * 2011-07-22 2018-09-20 이노코어 테크놀로지스 비.브이. 생물학적 활성 화합물의 조절된 방출을 위한 생분해성, 반-결정, 상 분리, 열 가소성 플라스틱의 멀티-블록 공중합체
US10441626B2 (en) * 2013-10-08 2019-10-15 Ferring Bv Microparticles comprising GNRH made by PGSS
GB201603280D0 (en) * 2016-02-24 2016-04-13 Ferring Bv Stable liquid gonadotropin formulation
DK3576771T3 (da) * 2017-01-31 2022-05-30 Veru Inc Sammensætninger og fremgangsmåder til langvarig frigivelse af antagonister for gonadotropin-frigivende hormon (gnrh)

Also Published As

Publication number Publication date
WO2020071912A1 (en) 2020-04-09
EP3860573A1 (en) 2021-08-11
CA3115186A1 (en) 2020-04-09
AU2019354528A1 (en) 2021-05-13
US20220062177A1 (en) 2022-03-03
JP2022504427A (ja) 2022-01-13
CN113226289A (zh) 2021-08-06

Similar Documents

Publication Publication Date Title
DOP2018000175A (es) Inhibidores de la proteína quinasa 1 que interactua con el receptor
CL2019000477A1 (es) Un esteroide 19 nor-c21-n-pirazolilo c3,3- disustituido cristalino.
DOP2018000297A (es) Derivado de glucagon, conjugado del mismo, composición que comprende el mismo y uso terapéutico del mismo
AR120567A2 (es) Recubrimiento de fertilizante, gránulo de fertilizante y fertilizante recubierto
BR112021006406A2 (pt) forma de dosagem de gonadotrofina coriônica humana (hcg) de liberação prolongada
CL2011000380A1 (es) Granulo para ser utilizado en la braquiterapia, que comprende una estructura insoluble o coloidal con radioisotopo, una matriz de polimero reabsorbible, que a su vez comprende particulas individuales, consistentes en sorbitol cubierto con un polimero biodegradable; y metodo para la fabricacion de dichos granulos.
CL2018001686A1 (es) Métodos y composiciones particularmente para el tratamiento del trastorno por déficit de atención (divisional solicitud 201701026)
DOP2016000109A (es) Formas sólidas de ácido {[5-(3-clorofenil) -3-hidroxipiridin-2-carbonil] amino} acético, composiciones, y usos de las mismas.
CL2022001722A1 (es) Derivados carboxi con propiedades antiinflamatorias
CR20160477A (es) Nanopartículas terapéuticas que comprenden un agente terapéutico, y métodos para su elaboración y uso
AR099572A1 (es) Artículos para fumar con liberación de un componente líquido que tiene un recubrimiento frágil
AR102780A1 (es) Composiciones farmacéuticas, su preparación y sus usos
ES2969895T3 (es) Métodos para obtener y usar inhibidores de PDE9
CY1122725T1 (el) Αποσμητικη συνθεση που περιλαμβανει ενα μειγμα αλφα, βητα και γαμμα κυκλοδεξτρινων
UY37444A (es) Derivados sustituidos de 6-(1h-pirazol-1-il)pirimidin-4-amina y su uso
CL2019002020A1 (es) Una composición farmacéutica que comprende un derivado de oxazina y su uso en el tratamiento o la prevención de la enfermedad de alzheimer.
CL2015003460A1 (es) Composiciones oftálmicas acuosas tópicas que contienen un derivado de 1h-indol-1-carboxamida y uso de estas para el tratamiento de una enfermedad oftálmica
IL283718A (en) Formulation of a sustained-release drug comprising an outer layer with an enzymatically degradable polymer, its preparation and method of production
DOP2020000093A (es) Uso de pirrolidonas heteroaromáticas fusionadas para el tratamiento y prevención de enfermedades en animales
CL2020000688S1 (es) Artículo sanitario absorbente. (divisional solicitud 201702698)
AR117833A1 (es) Composición prebiótica y su uso
TWD193827S (zh) Hillside slope fixing equipment
PL124883U1 (pl) Pieluszka
AR113548A1 (es) Base para el montaje de una plataforma de pesaje
CU20180079A7 (es) Inhibidores de la proteína quinasa 1 que interactúa con el receptor

Legal Events

Date Code Title Description
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]